Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment duration - PubMed
3 hours ago
- #immunotherapy
- #neurodegenerative diseases
- #anti-inflammatory
- Immunotherapies show potential in reducing risk of age-associated neurodegenerative diseases (NDDs) like Alzheimer's, Parkinson's, and ALS.
- A retrospective cohort study with 190,308 participants found AIT exposure significantly lowers NDD risk (RR = 0.47).
- Both sexes benefited equally from anti-inflammatory therapies (AITs), with immunomodulators showing the highest risk reduction (RR = 0.19).
- Longer treatment duration correlated with greater benefits, with risk reduction improving from RR = 0.94 (<1 year) to RR = 0.25 (>6 years).
- Older participants (75-79 years) experienced the strongest risk reduction, highlighting the importance of sustained therapy.